Cargando…

Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure

AIMS: In this prospective, placebo‐controlled, double‐blind, exploratory study, we examined early and more delayed effects of empagliflozin treatment on haemodynamic parameters (primary endpoint: cardiac output) and kidney function including parameters of acute kidney injury (AKI) in patients with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Thiele, Kirsten, Rau, Matthias, Hartmann, Niels‐Ulrik Korbinian, Möller, Marcus, Möllmann, Julia, Jankowski, Joachim, Keszei, András P., Böhm, Michael, Floege, Jürgen, Marx, Nikolaus, Lehrke, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288802/
https://www.ncbi.nlm.nih.gov/pubmed/35611683
http://dx.doi.org/10.1002/ehf2.13955
_version_ 1784748529136173056
author Thiele, Kirsten
Rau, Matthias
Hartmann, Niels‐Ulrik Korbinian
Möller, Marcus
Möllmann, Julia
Jankowski, Joachim
Keszei, András P.
Böhm, Michael
Floege, Jürgen
Marx, Nikolaus
Lehrke, Michael
author_facet Thiele, Kirsten
Rau, Matthias
Hartmann, Niels‐Ulrik Korbinian
Möller, Marcus
Möllmann, Julia
Jankowski, Joachim
Keszei, András P.
Böhm, Michael
Floege, Jürgen
Marx, Nikolaus
Lehrke, Michael
author_sort Thiele, Kirsten
collection PubMed
description AIMS: In this prospective, placebo‐controlled, double‐blind, exploratory study, we examined early and more delayed effects of empagliflozin treatment on haemodynamic parameters (primary endpoint: cardiac output) and kidney function including parameters of acute kidney injury (AKI) in patients with acute decompensated heart failure (HF). METHODS AND RESULTS: Patients with acute decompensated HF with or without diabetes were randomized to empagliflozin 10 mg or placebo for 30 days. Haemodynamic, laboratory, and urinary parameters were assessed after 6 h, 1 day, 3 days, 7 days, and 30 days of treatment. Median time between hospital admission and randomization was 72 h. Baseline characteristics were not different in the empagliflozin (n = 10) and placebo (n = 9) groups. Empagliflozin led to a significant increase in urinary glucose excretion throughout the study (baseline: 37 ± 15 mg/24 h; Day 1: 14 565 ± 8663 mg/24 h; P = 0.001). Empagliflozin did not affect the primary endpoint of cardiac index or on systemic vascular resistance index at any time point. However, empagliflozin significantly reduced parameters of AKI (urinary TIMP‐2 and IGFBP7 by NephroCheck® as indicators of tubular kidney damage), which became significant after 3 days of treatment [placebo: 1.1 ± 1.1 (ng/mL)(2)/1000; empagliflozin: 0.3 ± 0.2 (ng/mL)(2)/1000; P = 0.02] and remained significant at the 7 day time point [placebo: 2.5 ± 3.8 (ng/mL)(2)/1000; empagliflozin: 0.3 ± 0.2 (ng/mL)(2)/1000; P = 0.003]. CONCLUSIONS: In this study, empagliflozin treatment did not affect haemodynamic parameters but significantly reduced markers of tubular injury in patients with acute decompensated HF.
format Online
Article
Text
id pubmed-9288802
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92888022022-07-19 Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure Thiele, Kirsten Rau, Matthias Hartmann, Niels‐Ulrik Korbinian Möller, Marcus Möllmann, Julia Jankowski, Joachim Keszei, András P. Böhm, Michael Floege, Jürgen Marx, Nikolaus Lehrke, Michael ESC Heart Fail Short Communications AIMS: In this prospective, placebo‐controlled, double‐blind, exploratory study, we examined early and more delayed effects of empagliflozin treatment on haemodynamic parameters (primary endpoint: cardiac output) and kidney function including parameters of acute kidney injury (AKI) in patients with acute decompensated heart failure (HF). METHODS AND RESULTS: Patients with acute decompensated HF with or without diabetes were randomized to empagliflozin 10 mg or placebo for 30 days. Haemodynamic, laboratory, and urinary parameters were assessed after 6 h, 1 day, 3 days, 7 days, and 30 days of treatment. Median time between hospital admission and randomization was 72 h. Baseline characteristics were not different in the empagliflozin (n = 10) and placebo (n = 9) groups. Empagliflozin led to a significant increase in urinary glucose excretion throughout the study (baseline: 37 ± 15 mg/24 h; Day 1: 14 565 ± 8663 mg/24 h; P = 0.001). Empagliflozin did not affect the primary endpoint of cardiac index or on systemic vascular resistance index at any time point. However, empagliflozin significantly reduced parameters of AKI (urinary TIMP‐2 and IGFBP7 by NephroCheck® as indicators of tubular kidney damage), which became significant after 3 days of treatment [placebo: 1.1 ± 1.1 (ng/mL)(2)/1000; empagliflozin: 0.3 ± 0.2 (ng/mL)(2)/1000; P = 0.02] and remained significant at the 7 day time point [placebo: 2.5 ± 3.8 (ng/mL)(2)/1000; empagliflozin: 0.3 ± 0.2 (ng/mL)(2)/1000; P = 0.003]. CONCLUSIONS: In this study, empagliflozin treatment did not affect haemodynamic parameters but significantly reduced markers of tubular injury in patients with acute decompensated HF. John Wiley and Sons Inc. 2022-05-25 /pmc/articles/PMC9288802/ /pubmed/35611683 http://dx.doi.org/10.1002/ehf2.13955 Text en © 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Short Communications
Thiele, Kirsten
Rau, Matthias
Hartmann, Niels‐Ulrik Korbinian
Möller, Marcus
Möllmann, Julia
Jankowski, Joachim
Keszei, András P.
Böhm, Michael
Floege, Jürgen
Marx, Nikolaus
Lehrke, Michael
Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure
title Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure
title_full Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure
title_fullStr Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure
title_full_unstemmed Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure
title_short Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure
title_sort empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure
topic Short Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288802/
https://www.ncbi.nlm.nih.gov/pubmed/35611683
http://dx.doi.org/10.1002/ehf2.13955
work_keys_str_mv AT thielekirsten empagliflozinreducesmarkersofacutekidneyinjuryinpatientswithacutedecompensatedheartfailure
AT raumatthias empagliflozinreducesmarkersofacutekidneyinjuryinpatientswithacutedecompensatedheartfailure
AT hartmannnielsulrikkorbinian empagliflozinreducesmarkersofacutekidneyinjuryinpatientswithacutedecompensatedheartfailure
AT mollermarcus empagliflozinreducesmarkersofacutekidneyinjuryinpatientswithacutedecompensatedheartfailure
AT mollmannjulia empagliflozinreducesmarkersofacutekidneyinjuryinpatientswithacutedecompensatedheartfailure
AT jankowskijoachim empagliflozinreducesmarkersofacutekidneyinjuryinpatientswithacutedecompensatedheartfailure
AT keszeiandrasp empagliflozinreducesmarkersofacutekidneyinjuryinpatientswithacutedecompensatedheartfailure
AT bohmmichael empagliflozinreducesmarkersofacutekidneyinjuryinpatientswithacutedecompensatedheartfailure
AT floegejurgen empagliflozinreducesmarkersofacutekidneyinjuryinpatientswithacutedecompensatedheartfailure
AT marxnikolaus empagliflozinreducesmarkersofacutekidneyinjuryinpatientswithacutedecompensatedheartfailure
AT lehrkemichael empagliflozinreducesmarkersofacutekidneyinjuryinpatientswithacutedecompensatedheartfailure